About UsCROI 2017: Simple Risk Score Can Identify Gay Men Who May Have Acute HIV Infection
- Details
- Category: HIV/AIDS Epidemiology & Mortality
- Published on Sunday, 19 March 2017 00:00
- Written by Roger Pebody
A set of 7 simple questions about symptoms and risk factors identified three-quarters of gay men in Amsterdam who have acute (very recent) HIV infection, according to a study presented at the Conference on Retroviruses and Opportunistic Infections in Seattle last month. Using this risk score could identify gay men requiring HIV RNA testing, which can detect acute infections, in addition to HIV antibody testing.
CROI 2017: Better Depression Care Could Improve Outcomes for HIV Treatment Programs
- Details
- Category: Neurocognitive Problems
- Published on Sunday, 19 March 2017 00:00
- Written by Roger Pebody
Improved management of depression and other mental health problems has the potential to improve the outcomes of HIV treatment programs, Pamela Collins of the U.S. National Institute of Mental Health reported at the recent Conference on Retroviruses and Opportunistic Infections in Seattle. Mental health treatment should be integrated into HIV services in resource-limited settings, she said.
CROI 2017: Bone Density Improves in People Who Switch from Tenofovir DF to Tenofovir Alafenamide
- Details
- Category: Bone Loss
- Published on Thursday, 16 March 2017 00:00
- Written by Liz Highleyman
After 3 years, tenofovir alafenamide (TAF) for first-line HIV treatment was better at suppressing viral load and safer for the bones and kidneys than the older tenofovir disoproxil fumarate (TDF), researchers reported at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) last month in Seattle. Another study showed that people with low bone density who switched from TDF to TAF saw improved bone health, including a reduction in osteoporosis.
CROI 2017: Peer Navigators Improve Linkage to HIV Care and Retention in South African Study
- Details
- Category: Global Access
- Published on Sunday, 19 March 2017 00:00
- Written by Carole Leach-Lemens
Adults recently diagnosed with HIV who get help from peers to address personal barriers to care together with SMS check-in messages, appointment, and healthy living reminders had nearly twice the odds of being retained in care at 1 year of follow-up compared to those getting standard care at primary health clinics in South Africa according to findings presented at the recent Conference on Retroviruses and Opportunistic Infections.
CROI 2017: Long-Term Darunavir/Ritonavir Modestly Increases Risk of Cardiovascular Disease
- Details
- Category: Cardiovascular Disease
- Published on Thursday, 16 March 2017 00:00
- Written by Michael Carter
Long-term use of the boosted protease inhibitor darunavir (Prezista) modestly increases the risk of cardiovascular disease, according to data from the ongoing D:A:D study presented to the recent Conference on Retroviruses and Opportunistic Infections. Investigators identified an independent association between cumulative use of the drug over 5 years and heart attack and stroke.
CROI 2017: Finding Men with HIV -- and Keeping Them in Treatment
- Details
- Category: HIV/AIDS Epidemiology & Mortality
- Published on Sunday, 19 March 2017 00:00
- Written by Keith Alcorn
Specialized services to attract men to HIV testing and treatment may need to adopt several different formats in order to reach different sub-populations of men, suggesting there is no single service innovation that will boost uptake among men in sub-Saharan Africa, according to research from South Africa presented at last month’s Conference on Retroviruses and Opportunistic Infections.
CROI 2017: Dolutegravir Monotherapy Fails to Maintain Viral Suppression
- Details
- Category: HIV Treatment
- Published on Wednesday, 08 March 2017 00:00
- Written by Liz Highleyman
Dolutegravir used alone without other antiretrovirals was unable to keep viral load suppressed in some people who switched from a standard 3-drug combination regimen, according to research presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) last month in Seattle. But evidence continues to show that dolutegravir plus a single other drug can work well as maintenance therapy.
CROI 2017: How Does Vedolizumab Antibody Therapy Lead to Sustained Viral Remission?
- Details
- Category: Search for a Cure
- Published on Thursday, 16 March 2017 00:00
- Written by Liz Highleyman
HIV and its monkey cousin SIV can carry the alpha-4 beta-7 integrin receptor in their outer envelope, which helps the virus enter gut cells during early infection, according to research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. This finding may help explain how an antibody against alpha-4 beta-7 produced sustained viral remission in monkeys.
CROI 2017: Integrase Inhibitors May Increase Risk of IRIS in Late Presenters for HIV Treatment
- Details
- Category: HIV Treatment
- Published on Wednesday, 08 March 2017 00:00
- Written by Keith Alcorn
HIV integrase inhibitors such as dolutegravir and raltegravir may increase the risk of immune reconstitution inflammatory syndrome or IRIS, according to studies from the Netherlands and France presented last month at the Conference on Retroviruses and Opportunistic Infections in Seattle.
Web Design and Development by